Author's response to reviews

Title: Japan Useful Medication Program for Schizophrenia (JUMPs) - Long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia

Authors:

Jun Ishigooka (jun.ishigooka.jumps@gmail.com)
Kazuyuki Nakagome (nakagome@ncnp.go.jp)
Tetsuro Ohmori (tohmori@clin.med.tokushima-u.ac.jp)
Nakao Iwata (nakao@fujita-hu.ac.jp)

Version: 2 Date: 6 February 2013

Author's response to reviews:

January 17, 2013

Dr. Deesha Majithia

Executive Editor

BMC Psychiatry

Dear Dr. Majithia

On behalf of all authors, I would like to ask you to consider our manuscript entitled “Japan Useful Medication Program for Schizophrenia (JUMPs): Long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia” for publication in BMC Psychiatry as study protocol. This randomized, multicenter study is expected to yield evidence regarding the selection of antipsychotics which are aripiprazole, blonanserin, and paliperidone, for facilitating the recovery of social activity in patients with schizophrenia under ordinary healthcare setting in Japan.

All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere. All authors disclosed any competing interests in the manuscript.

We believe that findings from this study will be of special interest to the readers
of BMC Psychiatry.

Sincerely,

Jun Ishigooka, MD, PhD

Department of Psychiatry, Tokyo Women’s Medical University, School of Medicine, Japan

8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

Tel: +81-3-3353-8111

Facsimile: +81-3-3351-8979

E-mail: jun.ishigooka.jumps@gmail.com